Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal

Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet will receive an initial payment of $11.5 million.